| US benchmarks slid on Friday. The S&P 500 posted a 0.7% loss, while the Nasdaq fell 0.9%. The Dow gave up half of a percentage point, and the small-cap Russell 2K sold off for 1.5%. This morning, futures are pointing to a lower open. Dow and S&P 500 contracts are both down 0.8% in early morning trading. Get the Best Stocks to Trade In ANY Market!ð A.I. is the battle-tested technology that can help you make the most calculated trading decisions with impeccably precise timing. If you're looking to find the best trades in the markets, no matter the overall direction, you need to let the machines do the work. Our FREE Live Training is the best place to start. And as a bonus, our Pro Trader is also going to be revealing 4 explosive trades in real-time. This is live, with no replays. Don't miss out.
SAVE MY SEAT.
Volkswagen has valued Porsche at $78 billion for its upcoming IPO. The offering will raise up to $9.4 billion, and Porsche shares will begin trading on Sept. 29th.Bitcoin fell below $19,000 over the weekend, pulling back from its previous gains. The London Stock Exchange is closed for Queen Elizabeth II's funeral and will reopen Tuesday at 8 a.m. local time. AutoZone [AZO] - Last Close: $2,165.65 AutoZone is trending after a strong earnings report.
The auto parts store posted stronger-than-expected sales, earnings, and growth in its fiscal Q4 earnings release. Autozone reported earnings of $40.51 per share, beating the Street's $38.47 target and marking substantial growth from last Q4's $35.72 EPS. Revenues of $5.35 billion also beat the $5.16 billion estimate and were up substantially from the year-earlier quarter's $4.91 billion. The report also showed same-store sales growth of 6.2%. AZO is one of the top S&P 500 stocks with a 2.3% gain. My Take: Autozone has a reputation for being a good "recession stock." The thought is, more people will fix their car themselves when money is tight. It's unclear if that will be the case this time around, but the company has shown it can still deliver when the economic chips are down. Knowbe4 [KNBE] - Last Close: $17.30 Knowbe4 is soaring on news of a potential buyout deal. This morning, the SaaS company confirmed it had received a non-binding proposal from Vista Equity Partners to acquire all outstanding shares of the company. Under the terms of the deal, Knowbe4 shareholders would receive $24 per share in cash for their holdings. Knowbe4's board is considering the proposal, but a formal decision has yet to be announced. KNBE is one of this morning's top performers with a 22.5% gain. My Take: There's still some upside left between this stock's current price point, and it's proposed acquisition price. If the deal is accepted, the stock could easily close the gap. However, there's no telling how far it could fall if the sale falls through. Purple Co [PRPL] - Last Close: $2.79 Purple is moving higher on buy-out news. The high-tech mattress-in-a-box company announced this morning that it had received an unsolicited, non-binding buyout proposal from Coliseum Capital Management. The proposal offers $4.35 apiece to acquire all outstanding capital stock of PRPL, representing a 55% upside from the stock's Friday closing price. Purple's board of directors says it will review the proposal, but a formal decision has yet to be announced. PRPL is trading actively with a 33.0% gain on the potential buyout news. My Take: An entry at this price point could backfire if the deal doesn't go through. However, there's still 15%+ upside if it all works out. BlueBird Bio Inc [BLUE] - Last Close: $6.34 BlueBird is moving higher after announcing a regulatory breakthrough. The biotech company said late Friday that the US Food & Drug Administration granted accelerated approval to its Skysona gene therapy, a treatment for a rare neurodegenerative disease in adolescent boys. BlueBird also announced regulators have lifted a previous clinical development hold on the drug. The company anticipates that the commercial product will be available by the end of 2022 through a limited number of qualified treatment centers in the US. BLUE shot out to a 17% gain when the news broke, but the rally has since cooled off a tad. BLUE is trading actively with a 6.9% gain. My Take: This rally seems a little underwhelming considering the small size of this stock's float and the importance of this FDA ruling. It seems like investors have a nagging concern here, but I'm not sure what it is. This could be a good entry point for a swing trade. |
